Cellectar Biosciences, Inc.

Cellectar Biosciences is a clinical-stage biopharmaceutical company developing phospholipid drug conjugates (PDCs) for oncology applications. The company's primary asset is CLR 131 (iopofosine I-131), a PDC candidate currently in Phase 2 clinical studies for B-cell malignancies including relapsed or refractory Waldenstrom's macroglobulinemia, multiple myeloma, and non-Hodgkin's lymphoma. CLR 131 is also being evaluated in Phase 1 studies for pediatric solid tumors, lymphomas, malignant brain tumors, and head and neck cancer. The company is developing CLR 1900, a PDC chemotherapeutic program in preclinical stages targeting solid tumors.

Cellectar maintains collaborative relationships with Orano Med on the CLR 12120 Series and with LegoChem Bio. The company operates as a development-stage entity with a small team of 11 full-time employees headquartered in Florham Park, New Jersey. As a clinical-stage biotechnology company, Cellectar has no established revenue streams and operates primarily through research and development activities and capital financing. The company is incorporated in Delaware and trades on Nasdaq.